Abstract
Background Rising rates of antibiotic resistance have led to the use of broader spectrum antibiotics and increasingly compromise empiric therapy. Knowing the antibiotic susceptibility of a pathogen’s close genetic relative(s) may improve empiric antibiotic selection.
Methods Using genomic and phenotypic data from three separate clinically-derived databases of Escherichia coli isolates, we evaluated multiple genomic methods and statistical models for predicting antibiotic susceptibility, focusing on potentially rapidly available information such as lineage or genetic distance from archived isolates. We applied these methods to derive and validate prediction of antibiotic susceptibility to common antibiotics.
Results We evaluated 968 separate episodes of suspected and confirmed infection with Escherichia coli from three geographically and temporally separated databases in Ontario, Canada, from 2010-2018. The most common sequence type (ST) was ST131 (30%). Antibiotic susceptibility to ciprofloxacin and trimethoprim-sulfamethoxazole were lowest (<=72%). Across all approaches, model performance (AUC) ranges for predicting antibiotic susceptibility were greatest for ciprofloxacin (0.76-0.97), and lowest for trimethoprim-sulfamethoxazole (0.51-0.80). When a model predicted a susceptible isolate, the resulting (post-test) probabilities of susceptibility were sufficient to warrant empiric therapy for most antibiotics (mean 92%). An approach combining multiple models could permit the use of narrower spectrum oral agents in 2 out of every 3 patients while maintaining high treatment adequacy (∼90%).
Conclusions Methods based on genetic relatedness to archived samples in E. coli could be used to rescue older and typically unsuitable agents for use as empiric antibiotic therapy, as well as improve decisions to select newer broader spectrum agents.
Summary Rapid genomic approaches that capitalize on the association between genetic relatedness and phenotype can improve our selection of antibiotics, allowing us to rescue older drugs for empiric use and better select newer and broader spectrum agents.
Competing Interest Statement
ML has received honoraria/consulting income from Merck, Pfizer, Antigen Discovery, and Affinivax, and research support through his institution from Pfizer.
Funding Statement
We would like to acknowledge the funding support provided through the McLaughlin Accelerator Grant at the University of Toronto. DRM was supported through the Clinician Scientist Training Program at the University of Toronto, and a Canadian Institutes of Health Research Training Award. The project described was also supported by Cooperative Agreement Number U54GM088558 from the National Institute Of General Medical Sciences. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute Of General Medical Sciences or the National Institutes of Health.
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Yes
Data Availability
Genomic data will be uploaded and available through the National Center for Biotechnology Information’s Sequence Read Archive.
